Evan Levine, Co-Founder and CEO, PsyBio Therapeutics is pursuing a paradigm shift in the treatment of mental illness and other neurological disorders by using psychedelics and hallucinogenics. PsyBio biosynthesizes psilocybin and other psychoactive drugs from different plants  and fungi from genetically-modified bacteria. Under the influence of an anxiogenic molecule in a controlled setting, early clinical trials are showing a change in consciousness and rewiring of the brain to be able to address issues such as depression, anxiety, PTSD and substance abuse.